Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Prospective Study to Assess Metabolic Changes in Children and Adolescents Treated With Atypical Antipsychotics
This study is not yet open for participant recruitment.
Verified by Lawson Health Research Institute, April 2007
Sponsored by: Lawson Health Research Institute
Information provided by: Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT00480168
  Purpose

The purpose of this study is to observe patients aged 6-18 with various psychiatric diagnosis being treated with drugs called atypical antipsychotics to determine the effects of the drugs on growth, weight gain, and laboratory tests.


Condition Intervention
Adverse Effects
Drug: Atypical antipsychotics

U.S. FDA Resources
Study Type: Observational
Study Design: Natural History, Longitudinal, Defined Population, Prospective Study
Official Title: A Prospective Study to Assess Metabolic Changes in Children and Adolescents Aged 6-18 Treated With Atypical Antipsychotics

Further study details as provided by Lawson Health Research Institute:

Estimated Enrollment: 50
Study Start Date: May 2007
Estimated Study Completion Date: May 2007
Detailed Description:

Introduction: Antipsychotics have been used for many years to treat serious mental illnesses like schizophrenia and bipolar illness (manic depression). These older drugs carry a higher risk of side effects like shaking, stiffness, restlessness or uncontrolled movements. They may occur when the drugs are first taken, or later, after years of use. Newer drugs called atypical antipsychotics (ATA's) are much less likely to cause these problems. Their lack of these side effects and greater safety have led doctors to use them for other diseases in both adults and younger patients. They have proved to be helpful in aggression, impulsiveness, anxiety and mood swings. Unfortunately, a number of other side effects, such as weight gain, increased rates of diabetes and increases in cholesterol have also been identified. While a lot of current research into these side effects has been done in adults, there have been few studies with younger patients. The research so far has been brief and involved small numbers. This is especially important in this young and potentially vulnerable group of patients.

Study Methods: This research will study children and teens aged 6 to 18 who are being treated with the newer drugs for the first time. If agreeable to the patients and their parents or guardians, their doctors will prescribe one of the newer drugs and will measure the effects, if any, on weight, blood sugar, cholesterol as well as the improvement in their condition. Weight, height, and blood work will be done before the drug is started, and 6 and 12 months after they have been on it, comparing the results with their original values. The doctor, the patient and the parent or guardian will rate the patients' condition at these times, as well, to evaluate their improvement.

  Eligibility

Ages Eligible for Study:   6 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Atypical Antipsychotic naive patients who have agreed to take Atypical Antipsychotic medication upon the recommendation of their physician based on the child and their symptomsas per their usual patient care
  • Outpatients and inpatients
  • A wide range of patients including those with ADHD, Tourette’s disorder, anxiety, disruptive behavior and mood instability as well as psychosis
  • Children and adolescents aged 6 through 18 years
  • Both sexes
  • Females who have reached menarche and are sexually active who agree to use adequate birth control
  • Patients who are willing to give informed assent/consent
  • Guardians willing to give informed consent, if needed
  • No initiation of or changes of doses of other psychotropic medication prescribed for the indication of which the atypical antipsychotic is being prescribed in the preceding month.

Exclusion Criteria:

  • Patients with eating disorders (this condition might affect the expected weight and metabolic changes anticipated with the medications)
  • Concurrent medical conditions including diabetes or hyperlipidemia if, in the judgment of the treating physician, the use of atypical anti-psychotics would be contra-indicated. (patient safety)
  • Substance abuse (may effect the reliability of the patients or confound weight or metabolic effects of the medications)
  • Pregnant or lactating patients (patient safety)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00480168

Contacts
Contact: Tamison M Doey, MD FRCPC 519 258 0484 ext 138 drtamison@yahoo.com
Contact: Brenda Davidson 519 685 8500 ext 77130 brenda.davidson@lhsc.on.ca

Locations
Canada, Ontario
London Health Sciences Centre
London, Ontario, Canada, N6A 4G5
Windsor Regional Hospital
Windsor, Ontario, Canada, N8W 1L9
Sponsors and Collaborators
Lawson Health Research Institute
Investigators
Principal Investigator: Tamison M Doey, MD FRCPC University of Western Ontario, Canada
  More Information

Study ID Numbers: 11172
Study First Received: May 25, 2007
Last Updated: May 25, 2007
ClinicalTrials.gov Identifier: NCT00480168  
Health Authority: Canada: Health Canada

Keywords provided by Lawson Health Research Institute:
child
adolescent
weight gain
endocrine disruptors

Study placed in the following topic categories:
Body Weight
Weight Gain

ClinicalTrials.gov processed this record on January 13, 2009